Actinium Pharmaceuticals, Inc.
ATNM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.08 | -0.55 | 0.14 |
| FCF Yield | -87.32% | -35.14% | 3.22% | -16.99% |
| EV / EBITDA | 0.89 | -1.18 | -4.51 | -1.89 |
| Quality | ||||
| ROIC | -60.75% | -70.13% | -32.62% | -33.66% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.86 | 0.97 | -0.26 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -58.63% | – | – |
| Free Cash Flow Growth | 30.33% | -673.67% | 139.42% | 3.98% |
| Safety | ||||
| Net Debt / EBITDA | 1.91 | 1.46 | 3.18 | 3.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,406.07 | 0.00 | 0.00 | 0.00 |